Zoledronic acid-associated thrombotic thrombocytopenic purpura
G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), F. Cognetti(Sapienza University of Rome), Massimo Zeuli(Cancer Institute (WIA)), Alessandra Picardi(University of Rome Tor Vergata), Emilio Bria(Università Cattolica del Sacro Cuore), Maria Concetta Petti(Fondazione Gimema Onlus), Giovanna Meloni(Sapienza University of Rome), Paola Papaldo(Cancer Institute (WIA)), Alessandra Fabi(Agostino Gemelli University Polyclinic), Paolo Carlini(National Cancer Institute)
Cited by 11
Related Papers
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
|Blood|2011|402
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253